Alec Stranahan
BofA Securities, Research Division

Session with Sana Biotechnology. My name is Alec Stranahan. I cover SMid Biotech at Bank of America, and I'm also the analyst covering Sana. Pleased to be joined today by Steve Harr, President and CEO of Sana. Thanks for being here, Steve.

Steven Harr
President, CEO & Director

Thank you for having us.

Alec Stranahan
BofA Securities, Research Division

Yes, I appreciate it. Looking forward to the conversation.

Steven Harr
President, CEO & Director

It's actually a dry hot day in Vegas.

Alec Stranahan
BofA Securities, Research Division

Exactly. I guess maybe to start, Steve, I guess, significantly tightened Sana's focus over the past year. How would you sort of describe the company's identity today? Is it primarily a type 1 diabetes company? Is it in vivo CAR T company? Or is it -- is there a common thread maybe underlying?

Steven Harr
President, CEO & Director

As you know, we'll make forward-looking statements, so people can take a look at our 10-Q, which was filed last night actually for some really up-to-date risk factors. So Anyway, thank you for having us. And so the I guess what I would say is it's no different than when we started the company. And our goal is to engineer cells, right? And there are 2 different ways that you can engineer cells. One is you do it outside the body. And your goal in that scenario generally is to replace cells that are either missing or damaged, right, and transplant them in and hopefully can replace them. The second is we can engineer them in vivo or inside the person. And there, the goal is